Recent Updates
Recently added Catalysts
IMVT Positive Sentiment

Immunovant to Present at Upcoming Investor Conferences

Monday, November 13, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Immunovant, Inc. announced that its CEO, Pete Salzmann, will take part in several upcoming investor conferences, including the Stifel 2023 Healthcare Conference and Evercore ISI 6th Annual HealthCONx Conference. These events are scheduled for mid to late November 2023, providing opportunities for insights into the company's efforts in immunology and treatment of autoimmune diseases. The sessions will be accessible via live webcast, emphasizing Immunovant's transparency and engagement with the investment community.
Price reaction · baseline $32.63 (2023-11-10 close) · clean, no other IMVT news in the window
day 0 close
+0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunovant is actively engaging with investors through multiple conferences.
  • The company's CEO, Pete Salzmann, will provide insights during fireside chats.
  • Immunovant's focus on autoimmune diseases highlights its commitment to patient health.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
7.3%
average across 5 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
IMVT-1402
Phase 3 · Generalized Myasthenia Gravis

Full Press Release Details

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in fireside chats at the following investor conferences:
Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023, at 1:50 pm ET
Evercore ISI 6th Annual HealthCONx Conference on Tuesday, November 28, 2023, at 5:05 pm ET
Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30, 2023, at 11:30 am ET
The fireside chats will be webcast live and can be accessed at https://www.immunovant.com/investors/news-events. An archived webcast will be available for a limited time on Immunovant’s website.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit www.immunovant.com.
Chau Cheng, PhD, MBA
Vice President, Investor Relations
Head, Patient Advocacy

Frequently Asked Questions

What does Immunovant, Inc. focus on?

Immunovant focuses on enabling normal lives for individuals with autoimmune diseases.

When is the Stifel 2023 Healthcare Conference?

The Stifel 2023 Healthcare Conference is on November 15, 2023, at 1:50 pm ET.

Where can I watch the webcast of the fireside chats?

The webcast can be accessed at Immunovant's investor events page.

How does Immunovant develop its therapies?

Immunovant develops innovative therapies using anti-FcRn technology for autoimmune diseases.

Who is the CEO of Immunovant?

The CEO of Immunovant is Pete Salzmann, M.D.

ShareAdd on Google
Tags: IMVT Viatris Investor Conferences Healthcare Immunovant autoimmune diseases investor conferences Pete Salzmann Nasdaq IMVT
Last updated: Nov 13, 2023

Biotech snapshot

Cash runway
$798M liquidity · $41M/mo burn
~19 mo
Low dilution risk
Lead asset
IMVT-1402Phase 3
Generalized Myasthenia Gravis →

Catalyst track record

+85%
best trade around IMVT's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for IMVT.

See every catalyst's timing & PoA →